IMPACT OF THE BECLOMETASONE/FORMOTEROL/GLYCOPYRRONIUM ON SMALL AIRWAYS DYSFUNCTION IN COPD

Abstract

The article reviews the importance of small airway dysfunction and its effective management in chronic obstructive pulmonary disease (COPD). The MASCOT and TRIFLOW studies are discussed in detail. The extrafine beclometasone/ formoterol/glycopyrronium combination significantly improves small airway function, concurrently alleviates clinical symptoms, and reduces the risk of exacerbations. One of the key methods capable of detecting early changes is oscillometry.